hit counter
Calithera Biosciences, Inc. (CALA) Stock News Sentiment & Price - Sentifly
CALA - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Calithera Biosciences, Inc. (CALA)

USA
Biotechnology
NASDAQ
CALA Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CALA Latest news
Seeking Alpha
Neutral
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q3 2021 Results - Earnings Call Transcript
2021-11-09 21:35

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q3 2021 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
2021-11-09 16:05

-- Company strengthened precision oncology clinical pipeline through acquisition of mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals -- -- Cash, cash equivalents and investments totaled $84.5 million as of September 30, 2021 --

Benzinga
Negative
Why Did Calithera Shares Dropped To 52-Week Low In Premarket Friday?
2021-11-05 09:25

Calithera Biosciences Inc (NASDAQ: CALA) has decided to terminate its phase 2 KEAPSAKE trial based on a lack of clinical benefit observed in patients treated with telaglenastat in an interim analysis. The Phase 2 KEAPSAKE study was designed to evaluate the safety and anti-tumor activity of telaglenastat plus standard-of-care chemo-immunotherapy as front-line therapy for stage IV non-squamous non-small cell lung cancer (NSCLC) harboring KEAP1 or NRF2 mutation.

GlobeNewsWire
Neutral
Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer
2021-11-05 07:00

-- Dr. Kuriakose to succeed Keith Orford, MD, PhD, who will assume seat on Calithera Board of Directors -- Dr. Kuriakose to succeed Keith Orford, MD, PhD, who will assume seat on Calithera Board of Directors

GlobeNewsWire
Neutral
Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
2021-11-05 07:00

--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat

GlobeNewsWire
Neutral
Calithera Biosciences to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
2021-11-02 16:05

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company's third quarter 2021 financial results will be released on Tuesday, November 9, 2021. Company management will host a conference call on Tuesday, November 9, 2021 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

Benzinga
Positive
Calithera Posts Early-Data For Arginase Inhibitor In Cystic Fibrosis Trial
2021-11-01 10:20

Calithera Biosciences Inc (NASDAQ: CALA) shared interim safety and efficacy results from a Phase 1b trial evaluating CB-280, the company's investigational arginase inhibitor, in adults with cystic fibrosis (CF).  The data were shared at the North American Cystic Fibrosis Foundation Conference (NACFC).

GlobeNewsWire
Neutral
Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021
2021-11-01 07:00

-- CB-280 was well-tolerated, showed linear PK and demonstrated robust dose-related PD effects -- Encouraging trends seen in disease biomarkers including increased FeNO and decreased sweat chloride -- Early positive trend seen in FEV1, a safety endpoint

GlobeNewsWire
Neutral
Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021
2021-10-21 08:00

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company, today announced that data from its Phase 1b trial of CB-280, the company's investigational arginase inhibitor for the treatment of cystic fibrosis (CF), will be shared in a poster presentation at the North American Cystic Fibrosis Conference (NACFC), taking place virtually November 2-5, 2021.

Benzinga
Positive
Calithera Buys Two Oncology Candidates From Takeda For $45M
2021-10-19 06:51

Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK). The transaction terms include a total upfront cash payment to Takeda of $10 million and $35 million in Calithera Series A preferred stock.

Loading more news...